AU2015200027B2 — Contrast agents for applications including perfusion imaging
Assigned to Lantheus Medical Imaging Inc · Expires 2017-01-19 · 9y expired
What this patent protects
A method of imaging at least a portion of a cancer in a subject comprising: administering to the subject a contrast agent comprising an imaging moiety bound to 5 a compound, the compound selected from a pyridaben analog, pyridaben, a fenazaquin analog, fenazaquin, a pyrimidifen a…
USPTO Abstract
A method of imaging at least a portion of a cancer in a subject comprising: administering to the subject a contrast agent comprising an imaging moiety bound to 5 a compound, the compound selected from a pyridaben analog, pyridaben, a fenazaquin analog, fenazaquin, a pyrimidifen analog, and a tebufenpyrad analog; and scanning the patient using diagnostic imaging to produce an image of at least a portion of a cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.